SCHEMBL21361457

SCHEMBL21361457

C[C@@H]1CN(S(=O)(=O)N2CCc3cc(Cl)ccc3C2)CCCN(CC2CCCCC2)CCCN(S(=O)(=O)c2ccc(N(C)C)cc2)[C@@H]1C

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.35
PSEN1 P49768 4/20 0.35
PSEN2 P49810 4/20 0.35
APH1B Q8WW43 4/20 0.35
NCSTN Q92542 4/20 0.35
APH1A Q96BI3 4/20 0.35
PSENEN Q9NZ42 4/20 0.35
OPRK1 P41145 2/20 0.34
ALOX5 P09917 1/20 0.34
AKR1C3 P42330 1/20 0.34
AKR1C1 Q04828 1/20 0.34
HRH3 Q9Y5N1 3/20 0.33
PGR P06401 2/20 0.33
DRD2 P14416 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21361453 1.00 PDE4B (0.35) PDE4BPSEN1PSEN2APH1BNCSTN
SCHEMBL21361458 0.94 OPRK1 (0.37) PDE4BPSEN1PSEN2APH1BNCSTN
SCHEMBL21361454 0.94 OPRK1 (0.37) PDE4BPSEN1PSEN2APH1BNCSTN
SCHEMBL23102262 0.90 PDE4B (0.35) PDE4BPSEN1PSEN2APH1BNCSTN
SCHEMBL21361558 0.90 PSEN1 (0.42) PDE4BPSEN1PSEN2APH1BNCSTN
SCHEMBL21361557 0.90 PSEN1 (0.42) PDE4BPSEN1PSEN2APH1BNCSTN
SCHEMBL21361533 0.89 OPRK1 (0.39) PDE4BOPRK1ALOX5AKR1C3AKR1C1
SCHEMBL21361472 0.89 OPRK1 (0.40) PDE4BOPRK1ALOX5AKR1C3AKR1C1
SCHEMBL21361547 0.88 OPRK1 (0.39) PDE4BOPRK1ALOX5AKR1C3AKR1C1
SCHEMBL21361468 0.87 OPRK1 (0.39) PDE4BOPRK1ALOX5AKR1C3AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G PDE4B 3430/4885PSEN1 2622/4885PSEN2 3223/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G PDE4B 3457/4885PSEN1 2623/4885PSEN2 3291/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G PDE4B 3469/4885PSEN1 2566/4885PSEN2 3276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.